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Here we present a patient using anti-tumour necrosis factor-α
(anti-TNF-α) who developed disseminated nocardiosis, which
spontaneously resolved after discontinuation of anti-TNF-α.
A 75-year-old man presented with a 4-month history of fever,
night sweats and weight loss of 5 kg, accompanied by general
abdominal complaints consisting of anorexia, regurgitation and
nausea. For the past 6 years he had used anti-TNF-α 40 mg once
every 2 weeks, methotrexate 7.5 mg once weekly and predni-
sone 5mg daily for his rheumatoid arthritis. At presentation, anti-
TNF-α had been discontinued for 2 months and methotrexate
for 1 week. He was maintained on 5 mg prednisone daily only.
On physical examination no abnormalities were found.
His blood count was normal despite anaemia (haemoglobin
was 6.6 mmol/L (7.0–9.3 mmol/L), haematocrit 0.32 L/L
(0.36–0.48 L/L), leucocytes 3.6 × 109/L (2.5 × 109 to 8.2 × 109/
L) and thrombocytes 262 × 109/L (150 × 109 to 350 × 109/L)).
Urea was 4.8 mmol/L (3.6–4.8 mmol/L), creatinine 100 μmol/L
(62–106 μmol/L), sodium 127 mmol/L (135–145 mmol/L),
potassium 4.4 mmol/L (3.5–5.0 mmol/L) and C-reactive protein
was 56 mg/L (<10 mg/L). Liver enzymes were slightly elevated
(aspartate aminotransferase 37 U/L (<40 U/L), alaninew Microbe and New Infect 2015; 3: 10–11
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131 U/L (0–120 U/L) and lactate dehydrogenase 277 U/L
(<220 U/L)). An interferon-γ release assay that was performed
12 days after discontinuation of anti-TNF-α was negative.
Computed tomography (CT) scan of thorax and abdomen
showed a single lesion in the upper lobe of the right lung and
multiple lesions in the liver (Fig. 1a). Pathological evaluation of all
biopsies from the lesions in the liver showed central necrosis
withoutmalignant cells, neutrophils or fungi. TheGrocott stain for
fungi was negative and bacterial culture showed no growth. The
Ziehl–Neelsen stain did not show acid-fast bacteria. A positron
emission tomography (PET)/CT scan 2 weeks later showed an
increase of the lesion in the lung (Fig. 1b) and discrepancy in ﬂu-
orodeoxyglucose uptake in the various lesions in the liver, with
one active focus in the liver. At this point we considered a
disseminated infection caused by Mycobacterium tuberculosis, Acti-
nomyces, Nocardia or Coxiella burnetii as the most likely cause.
To rule out a disseminated M. tuberculosis infection the
interferon-γ release assay was repeated 3 months after discon-
tinuation of anti-TNF-α and remained negative. Furthermore,
new biopsies of the lesion in the lung and liver were taken for
histology and bacterial culture including mycobacteria. The bi-
opsies of the lung showed granulomatous inﬂammation. The
Ziehl–Neelsen stain did not show acid-fast bacteria. After 2
weeks a few chalky-white colonies consisting of gram-positive
branching bacteria were cultured. 16S rRNA sequencing com-
bined with biochemical tests identiﬁed the isolate as Nocardia
nova. The patient was advised to start intravenous antibiotic
treatment for disseminated Nocardia infection; however, he
refused. Immunosuppressive therapy had been decreased
recently and the patient continued to use 5 mg prednisone daily.
On follow up 1 month after the initial PET/CT scan, a chest
X-ray showed a remarkable decrease of the lesion in the lung.
The clinical condition of the patient had also improved. All
symptoms had subsided and he had gained 1 kg. A PET/CT scan
performed 2 weeks later showed a signiﬁcant decrease of the
lesions in the lung and a signiﬁcant decrease of the size and
amount of lesions in the liver (Fig. 1c).
As the patient was expected to need immunosuppressive
therapy in the future and because some small lesions in the liver
and the lungs had remained, although they were reduced, we
again advised the patient to receive treatment. This time the
patient agreed and treatment with imipenem and amikacin was
started. Six weeks later the patient showed further clinical and
radiological improvement and could be switched to an oral
regimen of trimethoprim-sulfamethoxazole. Due to complaints
about his joints, the prednisone dose was increased to 10 mg
daily. As trimethoprim-sulfamethoxazole interacts with meth-
otrexate and the rheumatoid arthritis remained in remissioniety of Clinical Microbiology and Infectious Diseases.
nses/by-nc-nd/3.0/)
FIG. 1. (a) Computed tomography (CT) scan of the thorax at pre-
sentation showing a cavitating lesion in the right upper lobe of the lung
measuring 15 × 9 mm. (b) positron emission tomography (PET)/CT
scan showing progression after 2 weeks to 20 × 26 mm. (c) PET/CT
scan showing regression of lesion to 14 × 18 mm. (d) CT scan showing
near complete resolution after 7 months of follow up.
NMNI Letter to the Editor 11with this prednisone dose, methotrexate was not restarted.
Seven months after presentation, the CT scan showed minimal
lesions in the lung (Fig. 1d).
To our knowledge, this is the ﬁrst report in the literature
describing a disseminated nocardiosis in an immunocompromised© 2014 New Microbes and New Infections published by Elsevier Ltd on beha
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tinuation of anti-TNF-α and methotrexate treatment. Since 2004,
nine cases have been reported of infections with Nocardia in pa-
tients using anti-TNF-α [1,2]. In none of these cases was sponta-
neous remission observed. Tumour necrosis factor-α plays an
important role in host defence and contributes to the function of
macrophages, granulocytes and cytotoxic effector cells in the
recognition and destruction of virus-infected cells and bacteria [3].
In mice infected with Nocardia brasiliensis and treated with anti-
TNF-α, the activity of peritoneal cells against Nocardia was signif-
icantly reduced compared with both cells of infected mice treated
with normal rabbit serum and cells of uninfected mice [4]. It is
conceivable that immune restoration after discontinuation of anti-
TNF-α leads to a more effective immune response to Nocardia.
Spontaneous resolution of Nocardia lung abscesses has been re-
ported in a patient with an advanced HIV infection in response to
highly active antiretroviral therapy [5]. In this case, recovery of the
immune system may explain the resolution of abscesses due to
Nocardia.
For disseminated nocardiosis, imipenem in combination with
amikacin is advised with surgical treatment of deep abscesses.
After initial intravenous treatment and clinical improvement, the
regimen can be switched to an oral alternative, usually
trimethoprim-sulfamethoxazole. In patients using methotrexate,
minocycline, ﬂuoroquinolones or linezolid can be advised as oral
alternatives because of the risk of drug interaction between
methotrexate and trimethoprim-sulfamethoxazole.
In conclusion, in patients on immunosuppressive therapy for
chronic inﬂammatory diseases who develop disseminated
Nocardia infection, decreasing the immunosuppressive therapy
may contribute to recovery. Adequate antibiotic treatment
should still be considered for patients in whom resumption of
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